Joint lesions in inflammatory bowel diseases: the analysis of the Moscow regional patient registry and a clinical case

Cover Page


Cite item

Full Text

Abstract

Rationale: Extraintestinal manifestations (EIM) of an inflammatory bowel disease (IBD) are a sign of its more severe course. Joint lesions are most common among IBD EIM.

Aim: To evaluate the prevalence and types of joint lesions in the population of IBD patients of the Moscow region.

Materials and methods: We performed a  retrospective analysis of medical files of the patients who were admitted to the Moscow Region Inflammatory Bowel Disease Center (MONIKI) for examination and treatment from August 1, 2019, to March 1, 2020. The study included 70 patients with confirmed diagnoses of IBD and confirmed or suspected involvement of the joints.

Results: Thirty six of 70 patients with IBD and EIM (51.43%) had been diagnosed with Crohn's disease (CD), and 34 (48.57%) with ulcerative colitis (UC). The CD group included more men (n=21, 58.33%), whereas their proportion in the UC group was 47.02% (n=16). The mean age at CD diagnosis in the UC and CD groups was comparable: 38.3±13.7  years in men with CD and 40.5±12.8 years in men with UC, 37.7±11.1 years in women with CD and 35.7±14.0 in women with UC. The most prevalent among all IBD patients were X-ray negative peripheral arthralgias. Among joint lesions confirmed by radiological diagnostics, sacroileitis was most prevalent both in all IBD patients (24.3%), as well as in the UC group (17.6%), whereas in the CD patients its frequency was the same as that of ankylosing spondyloarthritis (AS) (30.6% of the cases). AS ranked second in the prevalence of joint lesions in the UC group (8.8%) and all IBD (20%). Psoriatic arthritis was diagnosed only in the CD patients (2 / 36). We describe a clinical case of CD with AS, complicated with psoriatic rash, treated with a  monoclonal antibody to tumor necrosis factor alfa (anti-TNF-α).

Conclusion: Peripheral arthropathias were most prevalent among all joint lesions in the group studied. EIM mirror a more aggressive phenotype of the disease and higher glucocorticosteroids requirements. Administration of anti-TNF-α agents allows for the control of both intestinal IBD manifestations and of the joint syndrome. However, drug-associated skin adverse event can occur during treatment with this drug class. In such a case, it is possible to switch the biological therapy to another class of drugs that we have demonstrated with the given clinical example.

About the authors

O. V. Taratina

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.
Email: taratina.o@gmail.com
ORCID iD: 0000-0001-6112-6609

Olesya V. Taratina – MD, PhD, Research Fellow, Department of Gastroenterology; Associate Professor, Chair of Gastroenterology, Postgraduate Training Faculty

61/2 Shchepkina ul., Moscow, 129110

Россия

E. A. Belousova

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru
ORCID iD: 0000-0003-4523-3337

Elena A. Belousova – MD, PhD, Professor, Head of Department of Gastroenterology, Chief of Chair of Gastroenterology, Postgraduate Training Faculty

61/2 Shchepkina ul., Moscow, 129110

Россия

References

  1. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96(4):1116–22. doi: 10.1111/j.1572-0241.2001.03756.x.
  2. Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, Rogler G, Schoepfer AM. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106(1): 110–9. doi: 10.1038/ajg.2010.343.
  3. Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10(10):585–95. doi: 10.1038/nrgastro.2013.117.
  4. Veloso FT. Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? World J Gastroenterol. 2011;17(22):2702–7. doi: 10.3748/wjg.v17.i22.2702.
  5. Zippi M, Corrado C, Pica R, Avallone EV, Cassieri C, De Nitto D, Paoluzi P, Vernia P. Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients. World J Gastroenterol. 2014;20(46):17463–7. doi: 10.3748/wjg.v20.i46.17463.
  6. Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, Burisch J, De Vos M, De Vries AM, Dick AD, Juillerat P, Karlsen TH, Koutroubakis I, Lakatos PL, Orchard T, Papay P, Raine T, Reinshagen M, Thaci D, Tilg H, Carbonnel F; European Crohn’s and Colitis Organisation. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(3):239–54. doi: 10.1093/ecco-jcc/jjv213.
  7. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21(8):1982–92. doi: 10.1097/MIB.0000000000000392.
  8. Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008;40 Suppl 2: S253–9. doi: 10.1016/S1590-8658(08)60534-4.
  9. Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2011;7(4):235–41.
  10. Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, Navarini AA, French LE, Safroneeva E, Fournier N, Straumann A, Froehlich F, Fried M, Michetti P, Seibold F, Lakatos PL, Peyrin-Biroulet L, Schoepfer AM. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis. 2015;21(8):1794–800. doi: 10.1097/MIB.0000000000000429.
  11. Ивашкин ВТ, Шелыгин ЮА, Халиф ИЛ, Белоусова ЕА, Шифрин ОС, Абдулганиева ДИ, Абдулхаков РА, Алексеева ОП, Алексеенко СА, Ачкасов СИ, Барановский АЮ, Болихов КВ, Валуйских ЕЮ, Варданян АВ, Веселов АВ, Веселов ВВ, Головенко АО, Головенко ОВ, Григорьев ЕГ, Губонина ИВ, Жигалова ТН, Кашников ВН, Кизова ЕА, Князев ОВ, Костенко НВ, Куляпин АВ, Морозова НА, Муравьев АВ, Низов АА, Никитина НВ, Николаева НН, Никулина НВ, Одинцова АХ, Осипенко МФ, Павленко ВВ, Парфенов АИ, Полуэктова ЕА, Потапов АС, Румянцев ВГ, Светлова ИО, Ситкин СИ, Тимербулатов ВМ, Ткачев АВ, Ткаченко ЕВ, Фролов СА, Хубезов ДА, Чашкова ЕЮ, Шапина МВ, Щукина ОБ, Яковлев АА. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению болезни Крона. Колопроктология. 2017;60(2):7–29. doi: 10.33878/2073-7556-2017-0-2-7-29.
  12. Ивашкин ВТ, Шелыгин ЮА, Халиф ИЛ, Белоусова ЕА, Шифрин ОС, Абдулганиева ДИ, Абдулхаков РА, Алексеева ОП, Алексеенко СА, Ачкасов СИ, Барановский АЮ, Болихов КВ, Валуйских ЕЮ, Варданян АВ, Веселов АВ, Веселов ВВ, Головенко АО, Головенко ОВ, Григорьев ЕГ, Губонина ИВ, Жигалова ТН, Кашников ВН, Кизова ЕА, Князев ОВ, Костенко НВ, Куляпин АВ, Морозова НА, Муравьев АВ, Низов АА, Никитина НВ, Николаева НН, Никулина НВ, Одинцова АХ, Осипенко МФ, Павленко ВВ, Парфенов АИ, Полуэктова ЕА, Потапов АС, Румянцев ВГ, Светлова ИО, Ситкин СИ, Тимербулатов ВМ, Ткачев АВ, Ткаченко ЕИ, Фролов СА, Хубезов ДА, Чашкова ЕЮ, Шапина МВ, Щукина ОБ, Яковлев АА. Клинические рекомендации Российской гастроэнтерологической ассоциации и Aссоциации колопроктологов России по диагностике и лечению язвенного колита. Колопроктология. 2017;59(1):6–30.
  13. Duricova D, Sarter H, Savoye G, Leroyer A, Pariente B, Armengol-Debeir L, Bouguen G, Ley D, Turck D, Templier C, Buche S, Peyrin-Biroulet L, Gower-Rousseau C, Fumery M; Epimad Group. Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn's Disease: A French Population-Based Study. Inflamm Bowel Dis. 2019;25(2): 394–402. doi: 10.1093/ibd/izy254.
  14. Cohen R, Robinson D Jr, Paramore C, Fraeman K, Renahan K, Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis. 2008;14(6):738–43. doi: 10.1002/ibd.20406.
  15. Halling ML, Kjeldsen J, Knudsen T, Nielsen J, Hansen LK. Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. World J Gastroenterol. 2017;23(33):6137–46. doi: 10.3748/wjg.v23.i33.6137.
  16. Essers I, Ramiro S, Stolwijk C, Blaauw M, Landewé R, van der Heijde D, Van den Bosch F, Dougados M, van Tubergen A. Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatology (Oxford). 2015;54(4):633–40. doi: 10.1093/rheumatology/keu388.
  17. Белоусова ЕА, Абдулганиева ДИ, Алексеева ОП, Алексеенко СА, Барановский АЮ, Валуйских ЕЮ, Головенко АО, Головенко ОВ, Жигалова ТН, Князев ОВ, Куляпин АВ, Лахин АВ, Ливзан МА, Лубянская ТГ, Николаева НН, Никитина НВ, Никулина ИВ, Осипенко МФ, Павленко ВВ, Парфенов АИ, Рогачиков ЮЕ, Светлова ИО, Ткачев АВ, Ткаченко ЕИ, Халиф ИЛ, Чашкова ЕЮ, Щукина ОБ, Язенок НС, Яковлев АА. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018;46(5):445–63. doi: 10.18786/2072-0505-2018-46-5-445-463.
  18. Fiorino G, Omodei PD. Psoriasis and Inflammatory Bowel Disease: Two Sides of the Same Coin? J Crohns Colitis. 2015;9(9):697–8. doi: 10.1093/ecco-jcc/jjv110.
  19. Segaert S, Hermans C. Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents. Am J Clin Dermatol. 2017;18(6):771–87. doi: 10.1007/s40257-017-0296-7.
  20. Ungureanu L, Cosgarea R, Alexandru Badea M, Florentina Vasilovici A, Cosgarea I, Corina Șenilă S. Cutaneous manifestations in inflammatory bowel disease (Review). Exp Ther Med. 2020;20(1):31–7. doi: 10.3892/etm.2019.8321.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Taratina O.V., Belousova E.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies